S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
Bank Collapse Causes Gold Prices to Soar (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Bank Collapse Causes Gold Prices to Soar (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
66,000% upside on tiny biotech? (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
Bank Collapse Causes Gold Prices to Soar (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Bank Collapse Causes Gold Prices to Soar (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
66,000% upside on tiny biotech? (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
Bank Collapse Causes Gold Prices to Soar (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Bank Collapse Causes Gold Prices to Soar (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
66,000% upside on tiny biotech? (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
Bank Collapse Causes Gold Prices to Soar (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Bank Collapse Causes Gold Prices to Soar (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
66,000% upside on tiny biotech? (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
NYSE:BHC

Bausch Health Companies (BHC) Stock Forecast, Price & News

$8.22
-0.17 (-2.03%)
(As of 09/22/2023 ET)
Compare
Today's Range
$8.13
▼
$8.45
50-Day Range
$7.73
▼
$9.70
52-Week Range
$5.57
▼
$10.23
Volume
4.34 million shs
Average Volume
3.52 million shs
Market Capitalization
$2.97 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.50
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Bausch Health Companies MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
52.1% Upside
$12.50 Price Target
Short Interest
Bearish
6.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.42
Upright™ Environmental Score
News Sentiment
0.58mentions of Bausch Health Companies in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$55,352 Sold Last Quarter
Proj. Earnings Growth
9.42%
From $3.29 to $3.60 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

297th out of 968 stocks

Pharmaceutical Preparations Industry

121st out of 440 stocks

See Top Rated MarketRank™ Stocks Here

BHC stock logo

About Bausch Health Companies (NYSE:BHC) Stock

Bausch Health Companies Inc. operates as a diversified pharmaceutical company. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was incorporated in 2013 and is headquartered in Laval, Canada.

BHC Price History

BHC Stock News Headlines

September 23, 2023 | theglobeandmail.com
Closing Bell: Bausch Health Companies Inc down on Friday (BHC)
September 22, 2023 | barrons.com
MONDAY INVESTOR DEADLINE: Bausch Health Companies Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
September 24, 2023 | Chaikin Analytics (Ad)
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
September 22, 2023 | stockhouse.com
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Bausch Health Companies Inc. (BHC)
September 22, 2023 | americanbankingnews.com
Bausch Health Companies (NYSE:BHC) Raised to "Buy" at Jefferies Financial Group
September 20, 2023 | msn.com
Biggest stock movers today: Bausch Health, Pinterest, Instacart, Coty and more
September 20, 2023 | stockhouse.com
MONDAY DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Bausch Health Companies Inc. with Losses of $100,000 to Contact the Firm
September 20, 2023 | finance.yahoo.com
CANADA STOCKS-TSX ticks higher on materials boost; U.S. Fed decision on watch
September 24, 2023 | Legacy Research (Ad)
WARNING: Mandatory U.S. Dollar Recall is Weeks Away
If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.
September 20, 2023 | finance.yahoo.com
Why Bausch Health Stock Is Jumping Today
September 19, 2023 | finance.yahoo.com
Investing in Bausch Health (BHC): Navigating the Thin Line Between Value and Trap
September 15, 2023 | finance.yahoo.com
DocGo Inc. (DCGO) Moves 6.8% Higher: Will This Strength Last?
September 11, 2023 | finance.yahoo.com
InnovAge Holding Corp. (INNV) Soars 15.4%: Is Further Upside Left in the Stock?
September 10, 2023 | prnewswire.com
Bausch Health Companies Inc. (BHC) Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds BHC Investors of Securities Fraud Class Action Lawsuit Filed On Their Behalf
September 7, 2023 | benzinga.com
BHC Investors Should Contact Robbins LLP About Participating in the Class Action Against Bausch Health Companies Inc.
September 6, 2023 | theglobeandmail.com
Closing Bell: Bausch Health Companies Inc up on Wednesday (BHC)
September 6, 2023 | finance.yahoo.com
Bausch Health's Bausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRA(R)
September 3, 2023 | prnewswire.com
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Bausch Health Companies Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BHC
September 2, 2023 | prnewswire.com
Kessler Topaz Meltzer & Check, LLP Reminds BHC Investors of September 25, 2023 Deadline in Securities Fraud Class Action against of Bausch Health Companies Inc. and Urges Investors with Substantial Losses to Contact the Firm
August 25, 2023 | finance.yahoo.com
Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year?
August 24, 2023 | benzinga.com
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Bausch Health Companies Inc.(BHC) Investors of a Class Action Lawsuit and Upcoming Deadline
August 18, 2023 | stockhouse.com
INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Bausch Health Companies Inc. with Losses of $100,000 to Contact the Firm
August 14, 2023 | benzinga.com
BHC Investor Alert: Investors Should Contact Robbins LLP for Information About the Bausch Health Companies Inc. Class Action Lawsuit
August 12, 2023 | benzinga.com
BHC INVESTOR NOTICE: Bausch Health Companies Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
August 5, 2023 | finance.yahoo.com
Bausch Health Companies Inc. (NYSE:BHC) Q2 2023 Earnings Call Transcript
August 5, 2023 | businesswire.com
BHC INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Bausch Health Companies Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
August 3, 2023 | washingtonpost.com
Bausch: Q2 Earnings Snapshot
See More Headlines
Receive BHC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch Health Companies and its competitors with MarketBeat's FREE daily newsletter.

BHC Company Calendar

Last Earnings
8/03/2023
Today
9/23/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:BHC
CUSIP
N/A
CIK
885590
Web
www.bauschhealth.com
Phone
(514) 744-6792
Fax
514-744-6272
Employees
19,900
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.50
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+52.1%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.51)
Trailing P/E Ratio
N/A
Forward P/E Ratio
2.50
P/E Growth
N/A
Net Income
$-225,000,000.00
Net Margins
-2.23%
Pretax Margin
0.30%
Return on Equity
411.18%
Return on Assets
4.43%

Debt

Debt-to-Equity Ratio
74.20
Current Ratio
1.12
Quick Ratio
0.81

Sales & Book Value

Annual Sales
$8.12 billion
Price / Sales
0.37
Cash Flow
$7.03 per share
Price / Cash Flow
1.17
Book Value
$0.72 per share
Price / Book
11.42

Miscellaneous

Outstanding Shares
360,990,000
Free Float
311,354,000
Market Cap
$2.97 billion
Optionable
Optionable
Beta
0.98
20 Stocks to Sell Now Cover
20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Thomas J. Appio (Age 61)
    CEO & Director
    Comp: $4.73M
  • Mr. Thomas G. Vadaketh (Age 60)
    Exec. VP & CFO
    Comp: $1.35M
  • Ms. Seana Carson (Age 51)
    Exec. VP & Gen. Counsel
    Comp: $720.5k
  • Mr. Mirza Dautbegovic
    Sr. VP & COO
  • Ms. Kathleen Fitzpatrick
    Sr. VP & Chief HR Officer
  • Dr. Tage Ramakrishna M.D. (Age 49)
    Chief Medical Officer and Pres of R&D
  • Mr. Jeff Hartness
    Exec. VP of Market Access, Commercial Operations, Neurology, Generics & Gov. Affairs
  • Dr. Graham Jackson
    Sr. VP & Chief Quality Officer
  • Mr. Cees Heiman
    Sr. VP of Europe & Canada
  • Mr. Donald Pearl
    Sr. VP of Ortho Dermatologics

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













BHC Stock - Frequently Asked Questions

Should I buy or sell Bausch Health Companies stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bausch Health Companies in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BHC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BHC, but not buy additional shares or sell existing shares.
View BHC analyst ratings or view top-rated stocks.

What is Bausch Health Companies' stock price forecast for 2023?

3 brokers have issued 1 year target prices for Bausch Health Companies' stock. Their BHC share price forecasts range from $9.00 to $16.00. On average, they predict the company's stock price to reach $12.50 in the next twelve months. This suggests a possible upside of 52.1% from the stock's current price.
View analysts price targets for BHC or view top-rated stocks among Wall Street analysts.

How have BHC shares performed in 2023?

Bausch Health Companies' stock was trading at $6.28 at the beginning of 2023. Since then, BHC stock has increased by 30.9% and is now trading at $8.22.
View the best growth stocks for 2023 here.

Are investors shorting Bausch Health Companies?

Bausch Health Companies saw a increase in short interest in August. As of August 31st, there was short interest totaling 24,700,000 shares, an increase of 9.5% from the August 15th total of 22,550,000 shares. Based on an average daily volume of 2,490,000 shares, the days-to-cover ratio is presently 9.9 days. Approximately 6.9% of the shares of the stock are sold short.
View Bausch Health Companies' Short Interest.

When is Bausch Health Companies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our BHC earnings forecast.

How were Bausch Health Companies' earnings last quarter?

Bausch Health Companies Inc. (NYSE:BHC) posted its quarterly earnings data on Thursday, August, 3rd. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.75 by $0.06. The business earned $2.17 billion during the quarter, compared to analysts' expectations of $2.04 billion. Bausch Health Companies had a positive trailing twelve-month return on equity of 411.18% and a negative net margin of 2.23%.

What guidance has Bausch Health Companies issued on next quarter's earnings?

Bausch Health Companies issued an update on its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $8.45 billion-$8.65 billion, compared to the consensus revenue estimate of $8.35 billion.

What is Joseph C. Papa's approval rating as Bausch Health Companies' CEO?

43 employees have rated Bausch Health Companies Chief Executive Officer Joseph C. Papa on Glassdoor.com. Joseph C. Papa has an approval rating of 97% among the company's employees. This puts Joseph C. Papa in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Bausch Health Companies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bausch Health Companies investors own include Gilead Sciences (GILD), Micron Technology (MU), Constellation Software (CSU), Intact Financial (IFC), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Advanced Micro Devices (AMD) and Bank of America (BAC).

What is Bausch Health Companies' stock symbol?

Bausch Health Companies trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHC."

Who are Bausch Health Companies' major shareholders?

Bausch Health Companies' stock is owned by a variety of institutional and retail investors. Top institutional investors include Franklin Resources Inc. (4.58%), National Bank of Canada FI (3.64%), Lombard Odier Asset Management USA Corp (0.00%), Citadel Advisors LLC (0.00%), Jefferies Financial Group Inc. (0.97%) and Natixis (0.94%). Insiders that own company stock include Amy B Wechsler, Christina Ackermann, Joseph F Gordon, Robert Spurr, Russell Barrans, Sam Eldessouky, Schutter Richard U De, Seana Carson, Steven D Miller and William D Humphries.
View institutional ownership trends.

How do I buy shares of Bausch Health Companies?

Shares of BHC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bausch Health Companies' stock price today?

One share of BHC stock can currently be purchased for approximately $8.22.

How much money does Bausch Health Companies make?

Bausch Health Companies (NYSE:BHC) has a market capitalization of $2.97 billion and generates $8.12 billion in revenue each year. The company earns $-225,000,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis.

How many employees does Bausch Health Companies have?

The company employs 19,900 workers across the globe.

How can I contact Bausch Health Companies?

Bausch Health Companies' mailing address is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. The official website for the company is www.bauschhealth.com. The company can be reached via phone at (514) 744-6792, via email at ir@bauschhealth.com, or via fax at 514-744-6272.

This page (NYSE:BHC) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -